title: Molecular encapsulation of thalidomide with sulfobutyl ether-7 beta-cyclodextrin for immediate release property: enhanced in vivo antitumor and antiangiogenesis efficacy in mice.
abstract: Thalidomide's reported ability to inhibit tumor angiogenesis has led to clinical trials determining its effectiveness in combating various types of cancer. Since thalidomide exhibits low oral bioavailability due to limitations in solubility, inclusion complexation using sulfobutyl ether-7 beta-cyclodextrin was used to improve the delivery of thalidomide. Our main goals were to increase the solubility, bioavailability as well as chemical stability of thalidomide through complexation with anionic beta-cyclodextrin, to characterize the complex in solid state using differential scanning calorimetry, X-ray powder diffractometry, and to explore thalidomide's antitumorigenic and antiangiogenesis potential when administered orally as free and in combination with cyclodextrin to experimental animals. The aqueous solubility and aqueous alkaline stability of thalidomide was markedly increased by the SBE7betaCD complexation. Thalidomide administered orally in combination with SBE7betaCD, led to a significant delay in tumor formation as a result of improved cellular drug absorption, distribution through solubilization in experimental animals. The improved pharmacological efficacy of the thalidomide-cyclodextrin complex compared to free thalidomide in mouse melanoma model suggest that such a delivery system may be useful for the improved therapeutics of thalidomide, in vivo.
authors.affiliation: Department of Pharmaceutics, Bombay College of Pharmacy, Santacruz (E), Mumbai, India.
authors.forename: Rajendrakumar
authors.initials: R
authors.lastname: Kale
authors.forename: Pralhad
authors.initials: P
authors.lastname: Tayade
authors.forename: Madhusudan
authors.initials: M
authors.lastname: Saraf
authors.forename: Aarti
authors.initials: A
authors.lastname: Juvekar
mesh_terms: D020533:Angiogenesis Inhibitors / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use*; D000818:Animals; D001682:Biological Availability; D002152:Calorimetry, Differential Scanning; D004305:Dose-Response Relationship, Drug; D004355:Drug Stability; D005260:Female; D008546:Melanoma, Experimental / Q000098:blood supply / Q000188:drug therapy* / Q000473:pathology; D051379:Mice; D009389:Neovascularization, Pathologic; D012995:Solubility; D013792:Thalidomide / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use*; D014961:X-Ray Diffraction; D047392:beta-Cyclodextrins / Q000008:administration & dosage / Q000737:chemistry*
chemical_list: D020533:Angiogenesis Inhibitors; C103513:SBE7-beta-cyclodextrin; D047392:beta-Cyclodextrins; C093196:SBE4-beta-cyclodextrin; D013792:Thalidomide